15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.
about
PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancerChronic mild hypoxia protects heart-derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the SUR2A subunit of the ATP-sensitive K+ channelTroglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alphaThe non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesDirect angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activationDiabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERKGlitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma.15-Deoxy-Delta-Prostaglandin J(2) Upregulates the Expression of LPS-Induced IL-8/CXCL8 mRNA in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats.The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras.Pioglitazone modulates the proliferation and apoptosis of vascular smooth muscle cells via peroxisome proliferators-activated receptor-gamma.PPAR and immune system--what do we know?Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.Formation and signaling actions of electrophilic lipidsThiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism.Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions.Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products.Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.Mechanisms of disease: pulmonary arterial hypertension.The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells.Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity.PPARγ signaling and emerging opportunities for improved therapeutics.Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages.Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor.Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na+/H+ exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7.Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor gamma agonist, and their contribution to GW7845-induced apoptosis.15-deoxy-delta12,14-prostaglandin J2-mediated ERK signaling inhibits gram-negative bacteria-induced RelA phosphorylation and interleukin-6 gene expression in intestinal epithelial cells through modulation of protein phosphatase 2A activity.MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxInhibitory Effect of 3-(4-Hydroxyphenyl)-1-(thiophen-2-yl) prop-2-en-1-one, a Chalcone Derivative on MCP-1 Expression in Macrophages via Inhibition of ROS and Akt Signaling.15-deoxy-delta12,14 prostaglandin J2 synergizes with phorbol ester to induce proliferation in Swiss 3T3 cells independently of peroxisome proliferator-activated receptor gamma and PGD2 receptors.Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes.Phosphatidylinositol 3-kinase modulates vascular smooth muscle contraction by calcium and myosin light chain phosphorylation-independent and -dependent pathways.Troglitazone's rapid and sustained activation of ERK1/2 induces cellular acidosis in LLC-PK1-F+ cells: physiological responses.PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta.Angiotensin II Type 2 Receptor Inhibits Vascular Intimal Proliferation With Activation of PPARγ.
P2860
Q21328702-6C93B42C-1A42-4CEE-B49C-E9E456CE5308Q24681327-79F0F473-5940-4B15-A104-1EBC34A4E5E8Q24793384-1E6115E1-3A9E-4074-81EF-27885115D54FQ28238709-41C9F740-F486-4C97-9783-515AC9014841Q28485173-DB10D333-43D1-465B-B411-A09C945565F8Q28756314-F7906911-29DE-4585-B593-7B094D2B9527Q33196298-44329A34-A4E2-4874-8464-C373F476FD40Q33578102-115FBE27-946C-4979-BF4B-7EA2416F5244Q34189442-63599BAB-EE99-4083-ADA4-DDC3754201BBQ34309135-2D48A18A-4285-4C15-9D69-13AFCAAEA6C0Q34913467-0B5933CB-166E-4E38-B6C0-7DD0CE3EA218Q35596926-D2F7F87A-60A6-4FDF-81CD-DACD56BCF2C8Q35641787-86ABD9D8-04C2-4BAF-9A5A-0E8D980F91BFQ35804051-267DFF73-6D1C-4582-9279-F82B6C024070Q36078767-74481C5E-DEC2-42CA-A547-42A9AA2AB538Q36398075-0EC02E7F-E023-46BE-AB5C-6BBBFFB968C3Q36969863-C0347A67-7F40-4ED0-A879-B55C982DDB12Q37211832-07AE28F3-F0B7-4DFB-B38F-5E89BC2AD11CQ37512921-D165BF30-C69A-442B-9CC5-3624394491D4Q37822830-1FB8D378-E895-48A5-9287-6E76F8CA07D3Q37892336-97AA7E53-3307-40E9-B64D-CBF0AF3E559AQ37926558-D06B6114-7229-469F-AA41-04F1387CCE13Q38331308-D10F02CA-0819-491F-B3CE-9AE961829C67Q38359904-605B90A5-5F20-4C8B-B424-653472D92B84Q38856983-4E570E00-DA14-439C-A2B0-189CD98F01B6Q39332865-D36E04E4-8002-4328-BC9C-12252AFC0227Q39700445-C79D102C-D1FD-412E-A91A-08938E8516AFQ39864024-6351FD32-8587-4DD3-9DA4-D5FA95ED8482Q40056712-32D08A34-DE0A-4365-9F69-F10F120E8E09Q40215655-C2063086-CB5D-4ABF-ABEE-1AA94A2E227FQ40284163-764D8A91-DFB8-49C3-B580-B57B57417ED9Q40545008-B80E9900-0E9D-425B-BBF7-564D8C1DB641Q40726966-A2ED131A-C8F6-4662-8BA5-A663F453E5C6Q42182595-D4864ADA-FE05-4AA5-9E75-B99E6DDCF23CQ42802910-FDF8D131-133C-4EAE-A097-1F6B4E01EFBFQ44203920-D955C544-866A-4512-92AD-9831415FD729Q44612954-7202B29A-CFD9-4BD2-99CD-AA4C62A1AA46Q45248566-4D63CA76-ACE0-4FE7-B34C-B232774D906AQ46252518-9A9BA03B-5FF6-4451-97BD-1C6029027F35Q53482343-4868F476-1464-49BD-9B7F-D2E7A3BBEB89
P2860
15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
15-Deoxy-delta 12,14-prostagla ...... vascular smooth muscle cells.
@en
15-Deoxy-delta 12,14-prostagla ...... vascular smooth muscle cells.
@nl
type
label
15-Deoxy-delta 12,14-prostagla ...... vascular smooth muscle cells.
@en
15-Deoxy-delta 12,14-prostagla ...... vascular smooth muscle cells.
@nl
prefLabel
15-Deoxy-delta 12,14-prostagla ...... vascular smooth muscle cells.
@en
15-Deoxy-delta 12,14-prostagla ...... vascular smooth muscle cells.
@nl
P2093
P2860
P356
P1476
15-Deoxy-delta 12,14-prostagla ...... vascular smooth muscle cells.
@en
P2093
P2860
P304
48950-48955
P356
10.1074/JBC.M108722200
P407
P577
2001-10-30T00:00:00Z